Volume 30, No 11, Nov 2020

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 30 Issue 11, November 2020: 946-947

RESEARCH HIGHLIGHTS

When de novo-designed protein logics meet CAR-T therapies

Mingqi Xie^1,2,3,4,* , Peilong Lu^1,3,5,6,*

¹Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang, China
²Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, Hangzhou, Zhejiang 310024, China
³School of Life Sciences, Westlake University, Hangzhou, Zhejiang 310024, China
⁴Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, Zhejiang 310024, China
⁵Key Laboratory of Structural Biology of Zhejiang Province, Hangzhou, Zhejiang 310024, China
⁶Institute of Biology, Westlake Institute for Advanced Study, Hangzhou, Zhejiang 310024, China
Correspondence: Mingqi Xie(xiemingqi@westlake.edu.cn)Peilong Lu(lupeilong@westlake.edu.cn)

Protein logic gates acting at posttranscriptional levels are unique in being amenable to the control of both intracellular and intercellular biological processes. In a recent paper published in Science, Lajoie et al. engineered highly versatile colocalization-dependent protein switch that are activated upon detection of logic combinations (e.g., AND, OR and NOT) of specific cell surface antigens, providing another important asset for “universal” CAR-T therapies.

https://doi.org/10.1038/s41422-020-00419-z

FULL TEXT | PDF

Browse 832